Study of tozadenant from Biotie published in The Lancet for Parkinsons disease

Full data from the positive Phase IIb study evaluating tozadenant from Biotie Therapies in Parkinson's disease patients experiencing end of dose wearing off, have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. -"Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial". Lancet Neurol 2014; published online July 7. http://dx.doi.org/10.1016/S1474-4422(14)70148-6)

Previously released topline results for this study included clinically relevant and highly statistically improvements in 'off' time, 'on' time, UPDRS part III and UPDRS parts I-III. In addition to providing more details on these endpoints, further data published in Lancet Neurology include highly significant improvements in the clinician global impression of severity and clinician global impression of improvement in all tozadenant groups compared with placebo and patient global impression of improvement in the 120 mg BID group. Results of sensitivity analyses of the primary efficacy outcome using multiple methods were consistent with the improvements of the primary analysis.